CTEXLI (Chenodiol) Patent Expiration, LOE Window & CMS Spending

CTEXLI (Chenodiol) by Mirum Pharmaceuticals: FDA Orange Book LOE 2032-02-21, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $59,667 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMirum Pharmaceuticals
FDA Application & PathwayN219488 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2032-02-21
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($59,667 intro WAC)